Date: 13/12/2023	
Your Name:	Rachael Dodd
Manuscript Title:	"We need to work towards it, whatever it takes." Participation factors in the acceptability and feasibility
of lung cancer scr	eening in Australia: the perspectives of key stakeholders
Manuscript numl	per (if known): TLCR-23-623

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	X None		
9	Safety Monitoring Board or			
	Advisory Board			_
10	Leadership or fiduciary role	X None		
10	in other board, society,	_XNOTIC		
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	_XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
	Name			
N	one.			
1				

Date: 12-December-2023

Your Name: Ashleigh Rebecca Sharman

Manuscript Title: "We need to work towards it, whatever it takes." Participation factors in the acceptability and feasibility

of lung cancer screening in Australia: the perspectives of key stakeholders

Manuscript number (if known): TLCR-23-623

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for	x_None			
	lectures, presentations,				
	speakers bureaus, manuscript writing or educational events				
6	Payment for expert	xNone			
	testimony				
7	Support for attending meetings and/or travel	xNone			
8	Patents planned, issued or	xNone			
	pending				
9	Participation on a Data	x None			
9	Safety Monitoring Board or	x_None			
	Advisory Board				
10	Leadership or fiduciary role	x None			
	in other board, society,			_	
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	_xNone			
12	Receipt of equipment,	_xNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	x None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
N	None.				

Date: <u>1</u> 9/12/20	23
Your Name:	Mei-Ling Yap
	What would be and the condition between the law of the law of the conditions and the conditions of the conditions and the conditions are the conditions and the conditions are conditions are conditionally and the conditions are conditionally are conditionally are conditionally and the conditions are conditionally are conditional

Manuscript Title: "We need to work towards it, whatever it takes." Participation factors in the acceptability and feasibility of lung cancer screening in Australia: the perspectives of key stakeholders

Manuscript number (if known): TLCR-23-623

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NHMRC Investigator Grant (APP 2018108).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
Ü	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	_XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

The	e author is funded by a NHMRC Investigator Grant (APP 2018108).

Please place an "X" next to the following statement to indicate your agreement:

Date:	11 Dec 2023	
Your Name:	_Emily Stone	
Manuscript Tit	tle: "We need to work towa	ords it, whatever it takes." Participation factors in the acceptability and feasibility
of lung cancer	screening in Australia: the	perspectives of key stakeholders
Manuscript nu	ımber (if known):TLCR-2	3-623

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	
5			

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Speaker honoraria – Astra Zeneca, Merck Sharp & Dohme, The Limbic	
6	Payment for expert testimony	_xNone	
7	Support for attending meetings and/or travel	Astra Zeneca LOBES 2022	
8	Patents planned, issued or	x None	
8	pending	_XNone	
	-		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Ad hoc advisory board payment – Bristol Myers Squibb	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Deputy Board Chair Thoracic Oncology Group of Australasia, Co- Convenor Tobacco Control SIG Thoracic Society of Australasia, JTOCRR EiC	
11	Stock or stock options	xNone	
12	Receipt of equipment,	y None	
12	materials, drugs, medical	_xNone	
	writing, gifts or other services		
13	Other financial or non-	_xNone	
	financial interests		

I have received honoraria for lectures from AstraZeneca, Merck Sharp & Dohme, and The Limbic, support to attend meetings from AstraZeneca LOBES 2022 and have received ad hoc advisory board payment from Bristol Myers Squibb. I hold leadership roles as Deputy Board Chair for the Thoracic Oncology Group of Australasia and Editor in Chief of JTO Clinical and Research Reports. I am the past Co-Convenor Tobacco Control SIG Thoracic Society of Australasia.

Please place an "X" next to the following statement to indicate your agreement:

_x I certify that I have form.	e answered every questi	on and have not alter	ed the wording of any	of the questions on this

Date: <u>11/12/2</u>	te: 11/12/2023						
Vour Name	Henry Marshall						

Manuscript Title: "We need to work towards it, whatever it takes." Participation factors in the acceptability and feasibility of lung cancer screening in Australia: the perspectives of key stakeholders

Manuscript number (if known): TLCR-23-623

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Metro North Hospital and Health Service (Queensland, Australia) Clinical Academic Fellowship and an NHMRC Investigator Grant	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	

4	Consulting fees	xNone	
5	Payment or honoraria for	honoraria for lectures	AstraZeneca
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
	testimony		
	testimony		
7	Support for attending	travel	IASLC/WCLC
	meetings and/or travel		·
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	yes	TSANZ, IASLC (committee member)
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment,	_xNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services	N.	
13	Other financial or non-	_xNone	
	financial interests		

I'm supported by a Metro North Hospital and Health Service (Queensland, Australia) Clinical Academic Fellowship and an NHMRC Investigator Grant. I have received honoraria for lectures from AstraZeneca, funding for travel from the International Association for the Study of Lung Cancer (IASLC), and hold leadership roles for the Thoracic Society of Australia and New Zealand (convenor Tobacco and Related Substances Special Interest Group) and IASLC (committee member).

Please place an "X" next to the following statement to indicate your agreement:

_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>12/12/2</u>	023				
Your Name:	Joel Rhee				

Manuscript Title: "We need to work towards it, whatever it takes." Participation factors in the acceptability and feasibility of lung cancer screening in Australia: the perspectives of key stakeholders

Manuscript number (if known): TLCR-23-623

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x_None	
3	Royalties or licenses	_xNone	
4	Consulting fees	_xNone	

5	Payment or honoraria for	_xNone				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	xNone				
	testimony					
	-					
7	Support for attending	_xNone				
	meetings and/or travel					
8	Patents planned, issued or	_xNone				
	pending					
9	Participation on a Data	x_None				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	_xNone				
	in other board, society,					
	committee or advocacy group, paid or unpaid					
11	Stock or stock options	x None				
11	Stock of Stock options					
12	Receipt of equipment,	x None				
	materials, drugs, medical					
	writing, gifts or other					
	services					
13	Other financial or non-	xNone				
	financial interests					
Plea	Please summarize the above conflict of interest in the following box:					
N	one.					

Date	e: <u>12/12/2023</u>			-
You	r Name: Susan McCullo	ugh OAM		-
of lu	nuscript Title: "We need to ving cancer screening in Austr nuscript number (if known):	ralia: the perspectives of k	it takes." Participation factors in the acceptability and fea ey stakeholders	asibility
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to tl med In it	ne epidemiology of hypertentication, even if that medication	nsion, you should declare ition is not mentioned in t port for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other ite	e
	time name for disclosure is	the past so months.		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
2	Crants or contracts from	Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		

Royalties or licenses

Consulting fees

4

X___None

_X__None

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	X None			
9	Safety Monitoring Board or				
	Advisory Board			_	
10	Leadership or fiduciary role	X None			
10	in other board, society,	_XNOTE			
	committee or advocacy			_	
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	_XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
N	one.				
1					

Date: 13 December 2023	
Your Name: Nicole Rankin	
Manuscript Title: "We need to work towards it, whatever it takes." Participation factors in t	ne acceptability and feasibility
of lung cancer screening in Australia: the perspectives of key stakeholders	
Manuscript number (if known): TLCR-23-623	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Australian National Health and Medical Research Council (NHMRC) Ideas Grant (2019/GA65812)	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	_xNone	

4	Consulting fees	x None	
	5		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	xNone	
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or pending	xNone	
9	Participation on a Data	x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None	
11	Stock or stock options	_xNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone	
13	Other financial or non-	_xNone	
	financial interests		

This study was funded by an Australian National Health and Medical Research Council (NHMRC) Ideas Grant (2019/GA65812).		

Please place an "X" next to the following statement to indicate your agreement: